α-Synuclein genetic variants predict faster motor symptom progression in idiopathic Parkinson disease.
α-Synuclein Genetic Variants Predict Faster Motor Symptom Progression in Idiopathic Parkinson Disease

Beate Ritz1,2*, Shannon L. Rhodes1, Yvette Bordelon2, Jeff Bronstein2

1 Department of Epidemiology, University of California Los Angeles, Los Angeles, California, United States of America, 2 Department of Neurology, University of California Los Angeles, Los Angeles, California, United States of America

Abstract

Currently, there are no reported genetic predictors of motor symptom progression in Parkinson’s disease (PD). In familial PD, disease severity is associated with higher α-synuclein (SNCA) expression levels, and in postmortem studies expression varies with SNCA genetic variants. Furthermore, SNCA is a well-known risk factor for PD occurrence. We recruited Parkinson’s patients from the communities of three central California counties to investigate the influence of SNCA genetic variants on motor symptom progression in idiopathic PD. We repeatedly assessed this cohort of patients over an average of 5.1 years for motor symptom changes employing the Unified Parkinson’s Disease Rating Scale (UPDRS). Of 363 population-based incident PD cases diagnosed less than 3 years from baseline assessment, 242 cases were successfully re-contacted and 233 were re-examined at least once. Of subjects lost to follow-up, 69% were due to death. Adjusting for covariates, risk of faster decline of motor function as measured by annual increase in motor UPDRS exam score was increased 4-fold in carriers of the REP1 263bp promoter variant (OR 4.03, 95%CI:1.57–10.4). Our data also suggest a contribution to increased risk by the G-allele for rs356165 (OR 1.66; 95%CI:0.96–2.88), and we observed a strong trend across categories when both genetic variants were considered (p for trend = 0.002). Our population-based study has demonstrated that SNCA variants are strong predictors of faster motor decline in idiopathic PD. SNCA may be a promising target for therapies and may help identify patients who will benefit most from early interventions. This is the first study to link SNCA to motor symptom decline in a longitudinal progression study.

Introduction

Parkinson’s disease (PD) is a neurological condition characterized by progressive functional decline in motor function leading to disability and loss of quality of life [1]. Rate and severity of decline vary among patients but in all cases deterioration is inevitable as there are no current disease-modifying therapies that prevent or slow the neurodegenerative processes that cause PD [2]. More than a decade ago, clinical predictors of motor symptom progression were identified [3] including postural instability/gait disturbances, low Activities of Daily Living score, and dementia early in PD; since then only age at onset of symptoms has been added to this list [4]. One possible reason for the continuing paucity of information on risk factors for motor progression is that most PD patient cohorts with longitudinal data are comprised of non-representative groups of patients such as volunteers for clinical trials or referral patients at tertiary care centers. Such cohorts typically contain little information on non-clinical factors thereby presenting challenges for the identification of risk factors for progression beyond the most common clinical characteristics (such as age of symptom onset or motor subtype). Also, larger, mostly record-based studies are limited by the available outcomes (usually only comorbidities and mortality), typically lack of systematic motor symptom assessment, and generally have not collected lifestyle, environmental, or genetic risk factor data.

There are only a few population-based (community) studies publishing on motor progression using multiple motor symptom assessments over time, i.e., with longitudinally followed PD patients [3,5,6]. While one study [6] enrolled incident cases, two others [3,5] enrolled prevalent cases with long (>5 years) mean duration of disease prior to baseline assessment thereby preventing observation of the early stages of disease progression and therefore perhaps overlooking critical factors involved in faster motor symptom decline [7]. Furthermore, these previous longitudinal studies started with fewer than 250 PD cases at baseline and all had only 50–60% of subjects remaining for follow-up assessment rendering them under-powered to examine all but the most common predictors of motor decline.

Recent publications have called for prospective cohorts of PD patients assembled early in disease [8] and clinico-genetic studies [9] to help unlock the heterogeneity of PD and its progression. Identifying genetic predictors may aid clinical decision-making, help target patients for treatment trials, and improve our understanding of disease processes. Thus far, genetic predictors of motor decline have not been reported in longitudinally followed incident PD cohorts, largely due to the limited number of such cohorts with biosamples.
Prior research has demonstrated a robust association between risk of PD occurrence and genetic variation in the α-synuclein (SNCA) gene [10–16]. SNCA has been a candidate gene for idiopathic PD ever since the localization of the PARK1 loci to the SNCA gene region in a large Italian kindred [17] and identification of SNCA protein in Lewy bodies [18]. By far the most frequently investigated genetic variant in SNCA is the microsatellite D4S3401 (SNCA-Rep1), located in the promoter, approximately 10 kb upstream of SNCA, and first reported in the Alzheimer literature [19]. While the first PD association study of SNCA-Rep1 [20] did not observe a difference in allele distribution between PD patients with a family history of PD and unaffected controls, it did find a significant difference in allele distribution between PD patients without a family history and unaffected controls. Two following studies [21,22] observed a higher frequency of the 263 base pair (bp) repeat allele in PD cases compared with healthy controls. In 2006, a meta-analysis of 11 study populations including over 5000 subjects provided strong evidence that the 263bp allele was more frequent in cases increasing risk of PD (OR 1.43, 95% CI 1.22–1.69, dominant model) and that the 259bp allele was more frequent in controls decreasing risk of PD (OR = 0.85, 95% CI 0.76–0.96, dominant model); while the 261bp allele did not differ between PD cases and unaffected controls [10].

The linkage disequilibrium (LD) structure of SNCA suggests two distinct haplotype blocks, one covering an area from the 5' end of the gene (the region of SNCA-Rep1) to exon 4 and the other covering from intron 4 to the 3' region of the gene [23,24]. While many studies have investigated haplotypes containing the SNCA-Rep1 promoter variant in conjunction with other single nucleotide polymorphisms (SNPs) in the 5' region [10,21,24–32], use of promoter SNPs in place of or in addition to SNCA-Rep1 has not yet demonstrated improvement in risk estimation [10,32]. In the 3' region of SNCA most studies have investigated either rs356165 (first reported in Pals et al [26]; meta-analysis of 11 Caucasian studies, OR 1.32, 95% CI: 1.23–1.42 [33]) or rs356219 (first reported in Mueller et al [28]; meta-analysis of 18 Caucasian studies, OR = 1.20, 95% CI: 1.23–1.32 [33]). These two SNPs are in very high LD (D' = 1, r² = 0.962, LOD = 26.27 [34]) and either one uniquely identifies the two most common 3' region haplotypes as reported in Pankratz et al [35]. In contrast, correlation between SNCA-Rep1 and rs356219 was found to be very low (r² = 0.09) in a recent large study [36] supporting the hypothesis of two regions contributing to genetic risk of PD [37]. However, others hypothesized that the SNCA-Rep1 263bp allele arose on the haplotype background defined by the 'G' allele at rs356165 (or rs356219) thereby indicating a single genetic effect [23].

While findings from studies investigating SNCA 5' and 3' region genetic variants and age of onset of PD have been inconsistent [10,16,30,31,35–43], there is data supporting biologic effects for genetic variants in SNCA possibly modifying the PD phenotype. Both SNCA-Rep1 [44,45] and 3' region alleles [46] have been associated with increased gene expression; and 3' region risk alleles have been reported to correlate with higher plasma alpha-synuclein levels in PD patients [36]. Gene duplication [47,48] and triplication [49,50] in familial PD have been linked to increased mRNA expression levels [50–52] and to severity of disease [33,34]. Furthermore, the α-synuclein protein product, a major component of Lewy bodies [18], likely contributes significantly to PD neurodegeneration and consequently to motor symptom decline. Therefore, in this large, longitudinally followed population-based incident PD cohort we investigate, for the first time, whether genetic variation in the SNCA gene, a known risk factor for PD onset, contributes to PD motor symptom decline.

Methods

This study was approved by the human subjects committee of the University of Los Angeles (UCLA). Subjects participated in the study after written informed consent was obtained; prospective participants and their families/guardians were asked to discuss the consent documents; consent on behalf of participants deemed incapable of consenting was obtained from those determined to be legal proxies for the patient.

Study Population

This longitudinal patient cohort is derived from a case-control study that enrolled PD patients and population-based controls between 2001 and 2007 in Central California. Recruitment methods [55,56] and case definition criteria [57] have been described in detail elsewhere. Briefly, of 1,167 PD patients initially invited, 604 did not meet eligibility criteria primarily due to having a first physician diagnosis of PD more than 3 years prior to baseline. Of the 563 eligible patients, 473(84%) were examined by our movement disorder specialists (JB and YB) at least once; 104 did not meet published criteria for idiopathic PD [58] and 6 had incomplete data. The remaining 363 idiopathic PD patients compose the PD cohort that is the basis of this longitudinal follow-up investigation.

At first re-contact 83(22.9%) patients were deceased, 25(6.9%) withdrew, 9(2.5%) could not be found, and 4(1.1%) were too ill to participate. For follow-up, 242(66.6%) cases were successfully re-contacted with 6 patients participating by mail/phone only (no in-person follow-up exam and therefore not contributing to this analysis) and 3 patients re-classified by us during follow-up as not having idiopathic PD. Of 233 patients re-examined and confirmed to have idiopathic PD, 178(76.4%) were seen twice and 55 were seen only once during follow-up [21] were deceased prior to the second exam and 14 are still pending second exams, 8 were too ill to participate, 4 could not be not located, 3 withdrew, and 5 participated by mail/phone only. For these analyses, 232 of the 233 patients with at least one follow-up had SNCA genotype data available. All patients completed an interview to collect demographic and risk factor data; and provided blood samples for DNA.

Assessment of PD Motor Symptom Progression

Baseline and follow-up Unified Parkinson’s Disease Rating Scale (UPDRS) [59] exams were performed at a clinic near the patient’s residence or at that residence if the patient was unable to travel. Patients were examined off PD medications (i.e. overnight medication withdrawal prior to exam) whenever possible (82% of patients were off medication for baseline exam, 80% for follow-up exams). For patients and time points without an off exam, we estimated the off exam score by adding to the patient’s on exam score the difference of the last follow-up and the baseline motor scores divided by the interval of time (in years) between exams. We did not assume a linear association between the SNCA genetic variants and rates of motor progression since our analyses would be too
Determination of SNCA Variants

SNCA genetic variants were genotyped according to previously published methods [30,61]. The SNCA microsatellite Rep1 (D4S3461) was genotyped using fluorescent-labeled forward and reverse primers designed to the α-synuclein promoter locus (accession no. U46895), Fam5'-CCT GCC ATA TTT GAT TGG AA-3' and 5'-GAC TGG CCC AAG ATT AAC CA-3'. Detection and analysis was performed on an ABI 3730 DNA Analyzer (Applied Biosystems, Inc.) with Genemapper software. SNCA rs356165 in the 3' untranslated region (3'UTR) was genotyped on an ABI 7900 Genome Analyzer using ABI Taqman® chemistry.

Results

The characteristics of PD patients in this report are summarized in tables 1 and 2. We followed patients on average for 5.1 (std dev 2.2) years and categorized 35 (15.1%) patients as “fast progressors” for motor symptom decline as measured by the motor UPDRS. Fast progressors were older at time of PD diagnosis, had a lower UPDRS motor exam score at baseline, a shorter follow-up, and had lower baseline bradykinesia, rigidity, and tremor sub-scores (table 2), but did not differ from slow progressors in other risk factors including predominant motor type (akinetic [63]: 74% and 81%, respectively; p-value = 0.24). Deceased patients were older, had a higher baseline UPDRS motor score, higher bradykinesia and gait/balance sub-scores, a lower Mini Mental State Exam (MMSE) [64], and a higher Geriatric Depression Score (GDS) [65] than both slow and fast progressors. Participants lost to follow-up but not deceased were not different from slow progressors on demographics or risk factors. Neither deceased patients nor those lost to follow-up differed from slow progressors on SNCA-Rep1 or rs356165 genetic variants (table 3). Finally, although carriers of the 263bp-SNCA-Rep1 risk allele were on average younger (64 years) than non-carriers (67 years) at time of PD diagnosis, this difference was not formally statistically significant (p>0.10).

In logistic regression analyses adjusting for age, gender, smoking, duration of time between diagnosis and baseline assessment, and baseline UPDRS motor score, we observed no association between the SNCA-Rep1 259 allele and progression under a dominant genetic model although the odds ratio is in the expected (“protective”) direction (table 4). In contrast, PD patients carrying at least one 263bp allele in SNCA-Rep1 exhibited 4-fold higher odds of fast progression (OR = 4.03; 95% CI: 1.57–10.4; p = 0.002). Separately, the G allele of SNCA rs356165 increased risk of faster progression 60% (one copy) or 270% (two copies) under an additive genetic model (table 5). The G allele of SNCA rs356165 risk allele exhibited 4-fold higher odds of fast progression (OR = 4.03; 95% CI: 1.57–10.4; p = 0.002). Finally, although we did not observe statistical interaction, patients with the ‘GG’ risk genotype at rs356165 and without the SNCA-Rep1 263bp risk allele exhibited a smaller increase in risk of faster progression than patients with the ‘GG’ risk genotype and with at least one copy of the SNCA-Rep1 263bp risk allele; additionally, we observed a strong trend across categories of the combined genetic variants (table 7; p-value for trend 0.002).

Discussion

Heterogeneity in clinical presentation is widely acknowledged in PD [8] and the rate of disease progression and motor symptom decline is known to vary strongly [66]. The α-synuclein protein is a major component of Lewy bodies and participates in the molecular pathogenesis of PD. Mutations and multiplications of the SNCA gene cause familial parkinsonism and genetic variations are recognized as risk factors for idiopathic PD [50]. Here we present the first evidence that SNCA is an important and strong predictor of faster motor symptom decline in idiopathic PD: we observed a 4-fold higher risk of PD for carriers of the SNCA-Rep1 263bp allele and, when considering both Rep1 263bp and rs356165 ‘G’ allele, we observed a strong trend for faster motor decline across categories of the combined genetic variants. SNCA-Rep1 allelic variants and 3'UTR variants (including rs356165) are correlated with SNCA mRNA expression in human
postmortem brain tissues [46,67]. Furthermore, in familial parkinsonism with gene duplication or triplication increased mRNA expression has been linked to severity of disease (e.g. younger onset, faster decline, cognitive impairment) [50]. Thus, evidence that these PD-associated \(\alpha\)-synuclein variants have functional consequences is accumulating rapidly. In our population-based idiopathic PD cohort, both the \(\alpha\)-synuclein and Motor Symptom Progression in PD

Table 1. Demographic characteristics of Parkinson’s disease cohort members at baseline exam (2001–2007).

| All (n) | Slow Progressor | Fast Progressor | p* | Deceased | p† | Lost to Follow-up | p‡ |
|--------|-----------------|-----------------|----|----------|----|-------------------|----|
| Age at PD Diagnosis (mean±SD) | 66.4±9.9 | 69.6±8.6 | 0.07 | 73.9±6.8 | <0.01 | 64.9±13.4 | 0.46 |
| Age Range of Subjects | 35–88 | 50–83 | | 47–88 | | 34–84 | |
| Female (%) | 40.6 | 48.6 | 0.38 | 47.0 | 0.32 | 40.9 | 0.97 |
| Never Smokers (%) | 55.8 | 40.0 | 0.08 | 51.8 | 0.54 | 47.7 | 0.33 |
| Positive Family History of PD (%) | 14.2 | 14.3 | 0.99 | 13.2 | 0.83 | 20.5 | 0.30 |
| Non-Caucasian Race/Ethnicity (%) | 18.8 | 22.9 | 0.57 | 18.1 | 0.89 | 20.4 | 0.80 |
| ≤12 year of school (%) | 39.2 | 33.3 | 0.62 | 42.2 | 0.74 | 55.6 | 0.21 |

Abbreviations: PD = Parkinson’s disease; SD = standard deviation.

*P-value for chi-square test or t-test of fast vs. slow progressors.
†P-value for chi-square test or t-test of deceased participants vs. slow progressors.
‡P-value for chi-square test or t-test of lost participants vs. slow progressors.

Table 2. Phenotypic characteristics of Parkinson’s disease cohort members at baseline exam (2001–2007) and follow-up (2008–2010).

| All (n) | Slow Progressor | Fast Progressor | p* | Deceased | p† | Lost to Follow-up | p‡ |
|--------|-----------------|-----------------|----|----------|----|-------------------|----|
| Duration of PD prior to baseline | | | | | | | |
| mean±SD (years) | 1.84±1.3 | 2.01±1.6 | 0.50 | 2.08±1.35 | 0.16 | 1.88±1.16 | 0.86 |
| range | 0–7.1 | 0–6.7 | | 0–4.9 | | 0–4.5 | |
| Interval between exams | | | | | | | |
| mean±SD (years) | 5.20±2.2 | 4.26±2.1 | 0.02 | n.a. | n.c. | n.a. | n.c. |
| range | 0.85–9.1 | 1.14–8.7 | | n.a. | n.c. | n.a. | |
| Baseline UPDRS motor score | | | | | | | |
| mean±SD (points) | 20.5±9.7 | 15.8±7.5 | 0.01 | 27.0±13.6 | <0.01 | 20.3±10.5 | 0.89 |
| range | 4–49 | 3–31 | | 5–68.6 | | 3–51 | |
| Mean annual change in UPDRS motor score | | | | | | | |
| mean±SD (points per year) | 1.73±1.5 | 6.95±3.4 | <0.01 | n.a. | n.c. | n.a. | n.c. |
| range | 0–4.94 | 5–24.6 | | n.a. | n.c. | n.a. | |
| Baseline PD Subscores** | | | | | | | |
| Bradykinesia (mean±SD) | 6.89±4.0 | 4.96±3.4 | 0.01 | 9.31±5.3 | <0.01 | 6.80±4.3 | 0.89 |
| Rigidity (mean±SD) | 3.36±2.4 | 2.40±1.5 | <0.01 | 3.86±3.1 | 0.19 | 3.48±2.3 | 0.77 |
| Tremor (mean±SD) | 1.80±1.9 | 1.20±1.1 | 0.01 | 2.02±2.3 | 0.45 | 1.39±1.6 | 0.17 |
| Gait/Balance (mean±SD) | 2.92±2.0 | 2.81±2.1 | 0.78 | 5.18±3.3 | <0.01 | 3.43±2.6 | 0.23 |
| Baseline MMSE | | | | | | | |
| 28.2±2.4 | 27.8±1.9 | 0.44 | 26.5±3.0 | <0.01 | 27.9±2.5 | 0.61 |
| Baseline GDS | | | | | | | |
| 3.26±3.4 | 3.31±3.0 | 0.94 | 4.25±2.8 | 0.01 | 3.44±3.1 | 0.75 |

Abbreviations: SD = standard deviation; PD = Parkinson’s disease; yrs = years; n.a. = not applicable; n.c. = not calculated; UPDRS = Unified Parkinson’s Disease Rating Scale; MMSE = Mini Mental State Exam; GDS = Geriatric Depression Score.

*P-value for t-test of fast vs. slow progressors.
†P-value for t-test of deceased participants vs. slow progressors.
‡P-value for t-test of lost participants vs. slow progressors.

**PD subscores (bradykinesia, rigidity, tremor, gait/balance) calculated according to Louis (ref 3).

11Mini Mental State Exam score according to Folstein (ref 64).
12Geriatric Depression Score according to Yesavage (ref 65).

doi:10.1371/journal.pone.0036199.t001

doi:10.1371/journal.pone.0036199.t002
levels in idiopathic PD are strongly associated with progression as well as with disease risk.

Apart from clinical trials of mostly younger onset patients [68–73], and hospital-based studies of prevalent cases [4,66,74], only three prior population-based studies conducted in New York [3], Norway [5], and the UK [6] collected longitudinal UPDRS data for evaluating PD motor progression. All three population-based studies were limited by follow-up sample size (<150 subjects remaining after 4 years or more); whereas our study has 232 subjects at on average 5.1 years of follow-up, and thus is the largest population-based longitudinal study of PD motor symptoms in the literature to date. Additionally, two studies [3,5] assessed only prevalent cases with long mean duration of disease prior to baseline (6.8–9.1 years), thus missing early stages of disease progression, a potentially critical time for neurodegeneration of the dopamine system [66]. Faster motor decline in early disease is consistent with an early accelerated dopaminergic neurodegeneration and an exponential demise of neurons shortly after PD onset that levels off over time [75]. This early stage of PD might be the most sensitive and effective period for interventions aimed at slowing disease progression.

Our PD cohort is population-based and, thus, we expect it to adequately represent the range of disease phenotypes and treatment protocols found in the general U.S. PD population. Our study design also ensured representativeness of our patients to idiopathic PD patients seen in the health care system in general, different from more common PD progression studies that assembled homogeneous groups of very select patients from clinical trials or tertiary care facilities. The average age and age range of our PD patient cohort at diagnosis (68.3 years; range 34–88) is as expected in population based studies of PD; and similar to what was reported in the longitudinal study of incident PD in the UK (70.1 years; range 37–94) [6,76], and to the age range in both prevalence progression studies in NY (range 25–93) [3] and Norway (range 27–85) [77].

**Table 3.** SNCA Rep1 (D4S3481) and rs356165 genotypes of Parkinson’s disease cohort members.

| SNCA Rep1 genotypes, n(%) | Slow Progressor | Fast Progressor | p* | Deceased | p‡ | Lost to Follow-up | p‡ |
|---------------------------|-----------------|-----------------|----|----------|----|------------------|----|
| 259/259                   | 20 (10.2)       | 1 (2.9)         |    | 11 (13.6)| 1 (2.3)|                    |    |
| 259/261                   | 75 (38.1)       | 9 (25.7)        | 30 (37.0)|          | 23 (52.3)|                    |    |
| 259/263                   | 5 (2.5)         | 4 (11.4)        | 6 (7.4) |          | 3 (6.8) |                    |    |
| 261/261                   | 82 (41.6)       | 15 (42.9)       | 30 (37.0)|          | 13 (29.6)|                    |    |
| 261/263                   | 12 (6.1)        | 6 (17.1)        | 4 (5.0) |          | 4 (9.1) |                    |    |
| 263/263                   | 3 (1.5)         | 0 (0.0)         | 0.01 |          | 0.33 | 0.0 (0.0)         | 0.12|

SNCA rs356165

| AA                        | 63 (32.0)       | 8 (22.9)        | 29 (35.4)|          | 14 (31.8)|                    |    |
| AG                        | 101 (51.3)      | 16 (45.7)       | 4 (15.8) | 0.11     | 8 (18.2) |                    | 0.97|
| GG                        | 33 (16.7)       | 11 (31.4)       | 0.86 |          | 8 (18.2) |                    |    |

Abbreviations: SNCA = alpha-synuclein.

*P-value for chi-square test of fast vs. slow progressors.

‡P-value for chi-square test of deceased participants vs. slow progressors.

P-value for chi-square test of lost participants vs. slow progressors.

**One deceased subject had a genotype of 257/259 and one subject has not been genotyped for SNCA Rep1 and rs356165.

doi:10.1371/journal.pone.0036199.t003

**Table 4.** Logistic regression odds ratio (and 95%CI) for faster progression* by SNCA Rep1 genotypes defined by the 259 base pair allele vs others (dominant model).

| Primary Analysis | Subgroup #1 | Subgroup #2 |
|------------------|-------------|-------------|
| Slow Fast OR(95%CI) | p* | Slow Fast OR(95%CI) | p* | Slow Fast OR(95%CI) | p* |
| Subjects (n) | 197 35 | 125 24 | 174 32 |
| 259 non-carriers (%) | 49.2 60.0 | 47.2 62.5 | 50.6 59.4 | 0.0 (reference) | 0.0 (reference) |
| 259 carriers (%) | 50.8 40.0 | 52.8 37.5 | 49.4 40.6 | 0.88 (0.39–1.98) | 0.753 |
| All analyses are adjusted for age at diagnosis (continuous), gender (male/female), smoking status (never/ever), duration of time between PD diagnosis and baseline assessment (in years), and baseline UPDRS motor score. | | |
| Abbreviations: SNCA = alpha-synuclein; OR = odds ratio; CI = confidence interval; p = p-value; n = number. | | |
| Subgroup #1, subjects with off-medication exams only. | | |
| Subgroup #2, subject with complete UPDRS data at both baseline and follow-up exams. | | |
| Faster progression defined as ≥5 point change in motor UPDRS annually. | | |
| *Faster progression was defined as ≥5 point change in motor UPDRS annually. | | |
| P-value the additive (or allele dosage) genetic model. | | |
| doi:10.1371/journal.pone.0036199.t004 | | |
Moreover, the distributions of SNCA Rep1 and rs356165 variants observed in our cohort of PD cases are very similar to those observed for PD cases in studies indexed by PDGene (www.pdgene.org [33]). Thus, the results observed in our population-based cohort are more likely to be generalizable to the U.S. PD population than results of placebo arms of clinical trials that limit enrollment to a select age range or stage of disease.

Consistent with observations from a recent longitudinal imaging study [78] the motor symptoms of our PD patients age 66 and younger declined at a slower rate than those of our patients age 67 and older (2.13 points/year vs. 2.80 points/year, p = 0.043). Adjusting for age demonstrated that our observed genetic associations are independent of age. In fact, age-stratified analyses (<66 and >66), while underpowered, produced similar odds ratio estimates as the combined sample.

Due to the logistics of a population based study, we were unable to follow our patients on an annual or more regular basis, but our average annual rate of change measure accounts for differences in follow-up intervals. Moreover, our slow progressors were followed for a slightly longer interval thereby somewhat minimizing the effect size, we observed an overall mean change in UPDRS motor score of 2.52 points/year (average follow-up 5.1 years) which is very similar to the rate observed by the only other studies of incident PD cases [6] where 64% of lost subjects had died during follow-up. Relevant to our findings, when we examined the genetic variants of SNCA in those lost due to death and lost due to other reasons, we observed no differences from the comparison group of slow progressors (p>0.10).

Unlike many longitudinal PD studies, we attempted to examine all patients in a practically defined off PD medication state, but this was not achieved in about 20% of exams. While this could have caused non-differential outcome misclassification with regard to genetic factors and an underestimation of the rate of progression and the effect size, we observed an overall mean change in UPDRS motor score of 2.52 points/year (average follow-up 5.1 years) which is very similar to the rate observed by the only other studies of PD diagnosis and baseline assessment (in years), and baseline UPDRS motor score. Aberrations: SNCA = alpha-synuclein; OR = odds ratio; CI = confidence interval; p = p-value; n = number.

Table 5. Logistic regression odds ratio (and 95%CI) for faster progression* by SNCA Rep1 genotypes defined by the 263 base pair allele vs others (dominant model).

| Subgroup Analysis | Subgroup #1 | Subgroup #2 |
|-------------------|-------------|-------------|
| Slow, Fast OR(95%CI) | Slow, Fast OR(95%CI) | Slow, Fast OR(95%CI) |
| Subjects (n) | 197 35 | 263 non-carriers (%) | 16.7 31.4 2.76(1.57–4.84) | 16.7 34.4 3.85(2.09–7.10) |
| 263 carriers (%) | 10.2 28.6 4.03(1.57–10.4) | 7.2 33.3 9.00(2.63–30.8) | 10.3 31.2 4.53(1.69–12.1) |
| p | 0.004 | < 0.001 |

All analyses are adjusted for age at diagnosis (continuous), gender (male/female), smoking status (never/ever), duration of time between PD diagnosis and baseline assessment (in years), and baseline UPDRS motor score.

Table 6. Logistic regression odds ratio (and 95%CI) for faster progression* by SNCA rs356165 genotypes (additive model).

| Subgroup Analysis | Subgroup #1 | Subgroup #2 |
|-------------------|-------------|-------------|
| Slow, Fast OR(95%CI) | Slow, Fast OR(95%CI) | Slow, Fast OR(95%CI) |
| Subjects (n) | 197 35 | AA (%) | 32.0 22.9 1.00(reference) | 31.0 18.7 1.00(reference) | 174 32 |
| 263 non-carriers (%) | 89.9 71.4 1.00(reference) | AG (%) | 51.3 45.7 1.66(0.96–2.88) | 52.3 46.9 1.96(1.07–3.62) |
| GG (%) | 16.7 31.4 2.76(1.57–4.84) | 16.8 33.3 2.45(1.20–4.99) | 16.7 34.4 3.85(2.09–7.10) |
| p | 0.071 | 0.201 | 0.027 |
population-based incident study that estimated a mean change of 2.24 points/year (average follow-up 6.6 years) albeit this rate represents results from “on-on” exams [6].

Since motor symptom severity predicts increased mortality in PD independent of age and disease duration [79], identifying genetic predictors of faster motor decline is critical to pinpointing biological mechanisms as targets for therapies and identifying patients who will most benefit from early interventions. While replication of our results in similarly well-characterized population-based incidence PD cohorts that have been longitudinally followed is still needed, our findings strongly suggest that α-synuclein and related pathogenic pathways have great promise as potential disease modifying and therapeutic targets.

References

1. Global PD Survey Steering Committee (2002) Factors impacting on quality of life in Parkinson’s disease: results from an international survey. Mov Disord 17: 60–67.
2. Poewe W (2006) The need for neuroprotective therapies in Parkinson’s disease: a clinical perspective. Neurology 66: S2–9.
3. Louis ED, Tang MX, Cote L, Alfaro B, Mejia H, et al. (1999) Progression of parkinsonian signs in Parkinson disease. Arch Neurol 56: 334–337.
4. Jankovic J, Kapadia AS (2001) Functional decline in Parkinson disease. Arch Neurol 58: 1611–1615.
5. Maetzler W, Liepelt I, Berg D (2009) Progression of Parkinson’s disease in the population: a population-based study. Neurology 63: 1436–1441.
6. Evans JR, Mason SL, Williams-Gray CH, Folyntyne T, Brayne C, et al. (2011) The natural history of treated Parkinson’s disease in an incident, community-based cohort. J Neurol Neurosurg Psychiatry 82: 1112–1118.
7. Maetzler W, Lapert I, Berg D (2009) Progression of Parkinson’s disease in the clinical phase: potential markers. Lancet Neurol 8: 1158–1171.
8. Post B, Merkus MP, de Haan RJ, Speelman JD, CARPA Study Group (2005) Prognostic factors for the progression of Parkinson’s disease: a systematic review. Mov Disord 22: 1893–1851.
9. Wickremaratne MM, Ben-Shlomo Y, Morris HR (2009) The effect of onset age on the clinical features of Parkinson’s disease. Eur J Neurol 16: 450–456.
10. Maraganore DM, de Andrade M, Elbaz A, Farrer MJ, Ioannidis JP, et al. (2006) Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 296: 661–670.
11. Panetriz N, Nichols WY, Ebsasser VE, Pauwilo MW, Marek DK, et al. (2009) Alpha-synuclein and familial Parkinson’s disease. Mov Disord 24: 1123–1131.
12. Simón-Sánchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, et al. (2006) Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat Genet 41: 1308–1312.
13. Hamza TH, Zabetian CP, Tenesa A, Larderacher A, Montminyro J, et al. (2010) Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease. Nat Genet 42: 781–785.
14. International Parkinson Disease Genomics Consortium (2011) Imputation of sequence variants for identification of genetic risks for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet 377: 641–649.
15. Do CR, Tuny JM, Dorfman E, Kiefte AK, Drabant EM, et al. (2011) Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson’s disease. PLoS Genet 7: e1002411.
16. Carido LF, Costa E, de Mena L, Rahbaba R, Lorrondo-Betancor O, et al. (2011) A Search for SNCA 3’ UTR Variants Identified SNP rs506163 as a Determinant of Disease Risk and Onset Age in Parkinson’s Disease. J Mol Neurosci doi: 10.1007/s12031-011-9660-1.
17. Polymorphonous MH, Lavedan C, Lervoy E, Ide SE, Deheja A, et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson disease. Science 276: 2045–2047.
18. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, et al. (1997) Alpha-synuclein in Lewy bodies. Nature 388: 839–840.
19. Xia MS, Rohan de Silva HA, Rosi BL, Yamoka L, Rimmser JB, et al. (1996) Genetic studies in Alzheimer’s disease with an NACP/synuclein polymorphism. Ann Neurol 40: 207–215.
20. Parish A, Racette B, Zhang ZH, Chakraverty S, Rundle M, et al. (1998) Mutation, sequence analysis, and association studies of alpha-synuclein in Parkinson’s disease. Neurology 51: 1757–1759.
21. Krüger R, Vieira-Saecher AM, Kuhn W, Berg D, Müller T, et al. (1999) Increased susceptibility to sporadic Parkinson’s disease by a certain combined alpha-synuclein/apolipoprotein E genotype. Ann Neurol 45: 611–617.
22. Tan EK, Matsura T, Nagamura S, Khajavi M, Jankovic J, et al. (2001) Mutation, sequence analysis, and association studies of alpha-synuclein in Parkinson’s disease. Neurology 51: 1757–1759.
23. Krüger R, Vieira-Saecher AM, Kuhn W, Berg D, Müller T, et al. (1999) Increased susceptibility to sporadic Parkinson’s disease by a certain combined alpha-synuclein/apolipoprotein E genotype. Ann Neurol 45: 611–617.
24. Tai EK, Matsura T, Nagamura S, Khajavi M, Jankovic J, et al. (2001) Polymorphism of NACP/Rep1 in Parkinson’s disease: an etiologic link with essential tremor? Neurology 54: 1185–1198.
25. Miyre R, Toft M, Kachergis J, Huclian MM, Aslly JO, et al. (2008) Multiple alpha-synuclein gene polymorphisms are associated with Parkinson’s disease in a Norwegian population. Acta Neurol Scand 110: 320–327.
26. Trots L, Huidr I, Soldà G, Sironi F, Tesi S, et al. (2012) SNCA and MAPT genes: Independent and joint effects in Parkinson disease in the Italian population. Parkinsonism Relat Disord 18: 237–262.
27. Farrer M, Maraganare DM, Lockhart P, Singleton A, Leunick TG, et al. (2001) Alpha-synuclein gene haplotypes are associated with Parkinson’s disease. Hum Mol Genet 10: 1847–1851.
28. Pahl P, Lincoln S, Manning J, Heckman M, Skipper L, et al. (2004) Alpha-Synuclein promoter confers susceptibility to Parkinson’s disease. Ann Neurol 56: 591–595.
27. Mellick GD, Maraganore DM, Silburn PA (2005) Australian data and meta-analysis lend support for alpha-synuclein (NACP-Rep1) as a risk factor for Parkinson's disease. Neurosci Lett 375: 112–116.

28. Mueller JC, Fuchs J, Hofer A, Zimprich A, Lichtner P, et al. (2005) Multiple gene loci associated with Parkinson’s disease. Parkinsonism Relat Disord 11: 133–137.

29. Parsian AJ, Racette BA, Zhao JH, Sinha R, Patra B, et al. (2007) Association of alpha-synuclein gene haplotypes with Parkinson’s disease. Parkinsonism Relat Disord 13: 343–347.

30. Ross OA, Gosal D, Stoner JT, Lincoln SJ, Heckman MG, et al. (2007) Familial genes in sporadic disease: common variants of alpha-synuclein gene associate with Parkinson’s disease. Mech Ageing Dev 128: 378–382.

31. Winkler S, Hageman J, Lincoln S, Heckman M, Hasagvar K, et al. (2007) alpha-Synuclein and Parkinson disease susceptibility. Neurology 69: 1745–1750.

32. Sutherland GT, Halliday GM, Silburn PA, Mastaglia FL, Rowe DB, et al. (2005) Do polymorphisms in the familial Parkinsonism genes contribute to risk for sporadic Parkinson’s disease? Mov Disord 20: 833–838.

33. PDGene: A database for Parkinson’s disease genetic association studies. Available: http://www.pdgene.org/. Accessed 2012 Feb 14.

34. International HapMap Project. Available: http://hapmap.ncbi.nlm.nih.gov/cgi-perl/hbrowse/hapmap27_B36/. Accessed 2012 Feb 14.

35. Pankratz N, Wilk JB, Latourelle JC, DeStefano AL, Halter C, et al. (2009) Genome-wide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet 124: 593–605.

36. Mata IF, Shi M, Agarwal P, Chung KA, Edwards KL, et al. (2010) SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Ann Neurol 67: 1330–1336.

37. Simón-Sánchez J, van Hilten JJ, van de Warrenburg B, Post B, Berendse HW, et al. (2009) Genotype-phenotype correlation in familial Parkinson disease. Neuropsychiatry Genet 147B: 1222–1230.

38. Rajput A, Vilarin˜o-Gu¨ell C, Rajput ML, Ross OA, Soto-Ortolaza AI, et al. (2001) alpha-synuclein gene haplotypes are associated with Parkinson’s disease. Hum Mol Genet 10: 1847–1851.

39. Linnertz C, Simha-Rebel E, Böbel O (2003) Association testing with Mendel. Genet Epidemiol 29: 36–50.

40. Schiess MC, Zheng H, Soukup VM, Bonnen JP, Nauta HJ (2005) Parkinson’s disease subtypes: clinical classification and ventricular cerebrospinal fluid analysis. Parkinsonism Relat Disord 6: 69–76.

41. Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189–198.

42. Rajput A, Vilarin˜o-Gu¨ell C, Rajput ML, Ross OA, Soto-Ortolaza AI, et al. (2009) Alpha-synuclein polymorphisms are associated with Parkinson’s disease in a Saskatchewan population. Mov Disord 24: 2411–2414.

43. Schiess MC, Zheng H, Soukup VM, Bonnen JP, Nauta HJ (2005) Parkinson’s disease subtypes: clinical classification and ventricular cerebrospinal fluid analysis. Parkinsonism Relat Disord 6: 69–76.

44. Foltynie T, Brayne CE, Barker RA (2004) The cognitive ability of those with early Parkinson’s disease. Ann Neurol 55: 174–179.

45. Harrison MB, Wylie SA, Frysinger RC, Patrie JT, Huss DS, et al. (2009) Rate of clinical progression in Parkinson’s disease. A prospective study. Mov Disord 22: 931–945.

46. Elbaz A, Ross OA, Ioannidis JP, Soto-Ortolaza AI, Moisan F, Genetic Epidemiology Group. (2009) Do polymorphisms in the familial Parkinsonism genes contribute to risk for sporadic Parkinson’s disease? Mov Disord 24: 833–838.

47. Kay DM, Factor SA, Samii A, Higgins DS, Griffith A, et al. (2008) Genetic effect of SNCA 3’ region on the levels of SNCA-112 splicing variant. Neurology 70: 1461–1469.

48. Hadjigeorgiou GM, Xiromerisiou G, Gourbali V, Aggelakis K, Scarmeas N, et al. (2011) Gene dosage of alpha-synuclein locus triplication causes Parkinson’s disease. Ann Neurol 67: 1350–1356.

49. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, et al. (2003) Alpha-synuclein, pesticides, and Parkinson disease: a case-control study. Arch Neurol 60: 1245–1250.

50. Yesavage JA (1980) Geriatric Depression Scale. Psychopharmacol Bull 24: 799–811.

51. Fahn S, Marsden CD, Goldstein M, Calne D, eds. Recent developments in Parkinson’s disease. New York: MacMillan.

52. Shulman LM, Gruber-Baldini AL, Anderson KE, Fulham PS, Reich SG, et al. (2010) The clinically important difference on the unified Parkinson’s disease rating scale. Arch Neurol 67: 64–70.

53. Schrag A, Dodel R, Spotte A, Bormschein B,Siebert U, et al. (2007) Rate of clinical progression in Parkinson’s disease. A prospective study. Mov Disord 22: 931–945.

54. Linnertz C, Saucier L, Gr D, Cronin KD, Burke JR, et al. (2009) Genetic regulation of alpha-synuclein mRNA expression in various human brain tissues. PLoS One 4: e7480.

55. The National Parkinson Foundation. Parkoid Depression Group (1993) Effects of tocoherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 328: 176–183.

56. Olanow CW, Hauser RA, Gauger L, Malapira T, Koller W, et al. (1995) The effect of deprenyl and levodopa on the progression of Parkinson’s disease. Arch Neurol 52: 771–777.

57. Harrison MB, Wylie SA, Freisinger RC, Patric JT, Huss DS, et al. (2009) UPDRS activity of daily living score as a marker of Parkinson’s disease progression. Mov Disord 24: 224–230.

58. Greffard S, Verny M, Bonnet AM, Beini JY, Gallinari C, et al. (2007) Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch Neurol 64: 584–588.

59. Foltynie T, Brayne CE, Robbins TW, Barker RA (2004) The cognitive ability of those with early Parkinson’s disease. Ann Neurol 55: 174–179.

60. Sluiter CW, Oakes D, Kieburtz K, Real MF, Haas R, et al. (2002) Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59: 1541–1550.

61. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, et al. (2004) Levodopa and the progression of Parkinson’s disease. N Engl J Med 351: 2490–2500.

62. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, et al. (2009) A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 361: 1200–1207.

63. Hauser R, Beattie WS, Gwinn-Hardy K, et al. (2004) Synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms. Arch Neurol 61: 102–108.

64. Costello S, Walner A, Bronstein J, Cockburn M, Zhang X, et al. (2009) Parkin and Maneb exposure and Parkinson’s disease in the California Central Valley. Am J Epidemiol 169: 919–926.

65. Kang GA, Bronstein JM, Masterman DL, Reddels M, Crum JA, et al. (2005) Clinical characteristics in early Parkinson’s disease in a central California population-based study. Mov Disord 20: 1133–1142.

66. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ (1992) What features improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic study. Neurology 42: 1142–1146.

67. Fahn S, Elton RL (1987) Members of the UPDRS development committee: unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Calne D, eds. Recent developments in Parkinson’s disease. New York: MacMillan.

68. Kang GA, Bronstein JM, Masterman DL, Reddels M, Crum JA, et al. (2005) Clinical characteristics in early Parkinson’s disease in a central California population-based study. Mov Disord 20: 1133–1142.

69. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ (1992) What features improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic study. Neurology 42: 1142–1146.